Literature DB >> 3803418

Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects.

J Grevel, E Nüesch, E Abisch, K Kutz.   

Abstract

Extensive pharmacokinetic (PK) profiles after oral dosing of 300 mg cyclosporin A (CsA) were determined in whole blood by radioimmunoassay (RIA) in 14 healthy male volunteers, using two-compartment models with either first order (M1) or zero order (M0) absorption. According to zero order absorption the mean of the following PK parameters was determined: terminal half-life = 12.1 +/- 5.0 h, apparent volume of distribution at steady-state = 5.6 +/- 2.11 X kg-1, apparent clearance = 0.51 +/- 0.11 l X h-1 X kg-1. The time lag between drug ingestion and first blood level was short, 0.38 +/- 0.11 h. Drug absorption lasted for 2.8 +/- 1.6 h. The end of absorption was indicated in each individual by a sharp drop in blood levels. The observations support the assumption that CsA is absorbed in the upper part of the small intestine with a clear-cut termination (absorption window). This assumption may explain the high degree of variability in the bioavailability of CsA.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3803418     DOI: 10.1007/bf00606661

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Cyclosporin blood levels do correlate with clinical complications.

Authors:  E Irschik; H Tilg; D Niederwieser; G Gastl; C Huber; R Margreiter
Journal:  Lancet       Date:  1984-09-22       Impact factor: 79.321

2.  The value of serial serum trough cyclosporine levels in human renal transplantation.

Authors:  B D Kahan; C A Wideman; M Reid; S Gibbons; M Jarowenko; S Flechner; C T Van Buren
Journal:  Transplant Proc       Date:  1984-10       Impact factor: 1.066

3.  Pharmacokinetic study of cyclosporin A (Sandimmun) in patients with primary biliary cirrhosis.

Authors:  S Robson; J Neuberger; H P Keller; E Abisch; W Neiderberger; B von Graffenried; R Williams
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

4.  Cyclosporine kinetics in renal transplantation.

Authors:  R J Ptachcinski; R Venkataramanan; J T Rosenthal; G J Burckart; R J Taylor; T R Hakala
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

5.  Semi-automated high-performance liquid chromatographic method for the determination of cyclosporine in plasma and blood using column switching.

Authors:  H T Smith; W T Robinson
Journal:  J Chromatogr       Date:  1984-02-10

6.  Intestinal lymphatic absorption of cyclosporin A following oral administration in an olive oil solution in rats.

Authors:  C T Ueda; M Lemaire; G Gsell; K Nussbaumer
Journal:  Biopharm Drug Dispos       Date:  1983 Apr-Jun       Impact factor: 1.627

7.  Intravenous cyclosporine kinetics in renal failure.

Authors:  F Follath; M Wenk; S Vozeh; G Thiel; F Brunner; R Loertscher; M Lemaire; K Nussbaumer; W Niederberger; A Wood
Journal:  Clin Pharmacol Ther       Date:  1983-11       Impact factor: 6.875

8.  A radioimmunoassay to measure cyclosporin A in plasma and serum samples.

Authors:  P Donatsch; E Abisch; M Homberger; R Traber; M Trapp; R Voges
Journal:  J Immunoassay       Date:  1981

9.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

10.  Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.

Authors:  P J Wedlund; W S Aslanian; C B McAllister; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

View more
  17 in total

1.  Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses.

Authors:  M O Karlsson; A Lindberg-Freijs
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

2.  Enhancement of the oral absorption of cyclosporin in man.

Authors:  J Drewe; R Meier; J Vonderscher; D Kiss; U Posanski; T Kissel; K Gyr
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

3.  Pharmacokinetics of a single dose of ofloxacin in healthy elderly subjects using noncompartmental and compartmental models.

Authors:  C M Rademaker; R W Jones; L J Notarianni; A van Dijk; J H Glerum; J Verhoef
Journal:  Pharm Weekbl Sci       Date:  1989-12-15

4.  The effect of food and bile acid administration on the relative bioavailability of cyclosporin.

Authors:  A Lindholm; S Henricsson; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

5.  On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers.

Authors:  J P Reymond; J L Steimer; W Niederberger
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

6.  Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation.

Authors:  E A Mueller; J M Kovarik; J B van Bree; J Grevel; P W Lücker; K Kutz
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

Review 7.  Drug absorption in gastrointestinal disease and surgery. Clinical pharmacokinetic and therapeutic implications.

Authors:  P O Gubbins; K E Bertch
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

8.  Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis.

Authors:  J M Tredger; J Grevel; N Naoumov; C M Steward; A A Niven; B Whiting; R Williams
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Evidence for pre-hepatic metabolism of oral cyclosporine in children.

Authors:  K Hoppu; O Koskimies; C Holmberg; E L Hirvisalo
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

10.  Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells.

Authors:  Yu-Yuan Chiu; Kazutaka Higaki; Brien L Neudeck; Jeffrey L Barnett; Lynda S Welage; Gordon L Amidon
Journal:  Pharm Res       Date:  2003-05       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.